Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The FDA approved Wegovy (injectable semaglutide 2.4 mg) in June 2021 specifically for chronic weight management in adults with obesity or overweight plus weight-related health conditions. This landmark approval was based on the STEP clinical trials, which showed participants lost an average of 15% of body weight over 68 weeks. PlexusDx offers compounded semaglutide injections starting at $149 per month—without insurance requirements or membership fees—making this proven therapy more accessible.

How FDA Approval Works for Semaglutide Weight Loss

Regulatory approval for weight-loss medications involves rigorous testing through multiple clinical trial phases. The FDA requires manufacturers to demonstrate that a drug is both safe and effective for its intended use before allowing it on the market. Semaglutide underwent years of research involving thousands of participants to prove its role in sustained weight reduction.

Wegovy's approval was significant because previous weight-loss medications had limited effectiveness or tolerability. The STEP trials enrolled over 4,500 participants across different age groups and metabolic backgrounds, making the approval evidence particularly robust. Participants who received semaglutide combined with lifestyle counseling achieved clinically meaningful weight loss compared to those on placebo alone.

FDA approval does not mean a medication is risk-free—it means benefits outweigh risks for the approved population. Healthcare providers use this stamp of approval to guide prescribing decisions and patient selection. The approval letter specifies exact dosing regimens, patient populations, and required monitoring, which helps standardize safe use.

Clinical Evidence Behind Semaglutide's Weight Loss Benefits

The STEP clinical trial program demonstrated that semaglutide reduces appetite and promotes weight loss through GLP-1 receptor activation in the brain. Participants receiving the 2.4 mg dose (Wegovy's approved strength) lost an average of 15% of initial body weight, while some achieved reductions of 20% or more. These results held consistent across different demographics, including people with type 2 diabetes and those without.

Beyond weight reduction, clinical data showed semaglutide improved cardiovascular risk factors including blood pressure and cholesterol levels. Participants also reported better blood sugar control and reduced cravings for high-calorie foods. The weight loss began within the first 4 weeks and continued to improve through week 68, with maintained results during extension phases of the trials.

Long-term safety monitoring revealed that most side effects were mild to moderate and manageable with gradual dose adjustment. Nausea, constipation, and vomiting were the most common effects, typically declining after the first few weeks. These findings supported the FDA's determination that semaglutide's benefits justified its approved use in appropriate patient populations.

Semaglutide vs. Other FDA-Approved Weight Loss Medications

Several medications hold FDA approval for weight loss, but they differ in effectiveness, mechanism, and patient tolerability. Older options like orlistat (Xenical) work locally in the digestive system and produce more modest weight loss of 5-7%. Newer GLP-1 drugs like semaglutide achieve superior results by working on appetite-control centers in the brain.

Tirzepatide (Mounjaro/Zepbound) is another FDA-approved dual-action medication that targets both GLP-1 and GIP receptors, potentially offering additional weight loss compared to semaglutide alone. Clinical trials show tirzepatide achieved up to 22% weight reduction at the highest dose. PlexusDx offers both compounded semaglutide injections and tirzepatide injections, plus a dual-compound option (GLP-Squared Injection) for patients seeking personalized therapy.

The choice between semaglutide and other approved options depends on individual response, tolerance, and clinical goals. Some patients achieve excellent results with semaglutide while others respond better to tirzepatide or combination approaches. PlexusDx's Precision Peptide Genetic Test can identify genetic variants affecting GLP-1 and GIP receptor function, helping guide personalized medication selection.

Accessing FDA-Approved Semaglutide Through PlexusDx

PlexusDx offers compounded semaglutide injections from licensed 503A compounding pharmacies, delivering the same active ingredient as Wegovy at significantly lower cost. Compounded medications are not FDA-approved in the traditional sense, but they are manufactured under strict pharmaceutical standards and regulatory oversight. PlexusDx's semaglutide injection starts at $149 per month across all three commitment tiers—your dose may need to go up, but your price won't.

No insurance is required, no membership fees apply, and HSA/FSA accounts are eligible for payment. PlexusDx serves all 50 states and provides telemedicine consultations with prescribing providers who evaluate candidacy, adjust dosing, and monitor progress. Patients receive their medication shipped directly to their home with ongoing clinical support.

Those seeking additional personalization can add the Precision Peptide Genetic Test ($99 after first month) to understand how their genetic makeup influences GLP-1 and GIP receptor function, FTO metabolism, and melanocortin-4 signaling. This genetic insight helps inform whether semaglutide alone, tirzepatide alone, or the dual GLP-Squared Injection may offer the best individual response.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Wegovy FDA-approved for weight loss?

Yes, the FDA approved Wegovy (semaglutide 2.4 mg injection) in June 2021 for chronic weight management in adults with obesity or overweight with weight-related conditions. It is based on strong clinical evidence from the STEP trials demonstrating an average 15% body weight reduction. PlexusDx offers compounded semaglutide with the same active ingredient at $149/month without insurance requirements.

How much weight can you lose with semaglutide?

Clinical trial data showed participants using semaglutide lost an average of 15% of their initial body weight over 68 weeks, with some achieving 20% or greater reductions. Results vary based on individual metabolism, adherence to lifestyle changes, and dose escalation. PlexusDx provides dose escalation over time to maximize your individual response while keeping your monthly cost flat.

What is the difference between Wegovy and PlexusDx semaglutide?

Wegovy is the FDA-approved branded version manufactured by Novo Nordisk, while PlexusDx offers compounded semaglutide from licensed 503A pharmacies with the same active ingredient. Both deliver semaglutide injections, but PlexusDx costs significantly less ($149/month) and requires no insurance or membership. PlexusDx also offers telemedicine consultations and optional genetic testing for personalized therapy selection.

Are there side effects with semaglutide for weight loss?

The most common side effects are nausea, constipation, and vomiting, typically mild to moderate and declining after the first few weeks of use. Slower dose escalation reduces side effect severity. Serious side effects are rare but can include pancreatitis and gallbladder issues—PlexusDx providers screen for contraindications and monitor patients during treatment to ensure safety.

How does PlexusDx personalize semaglutide therapy?

PlexusDx's Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence your metabolic response to GLP-1 therapies. This genetic insight helps determine whether semaglutide alone, tirzepatide, or the dual GLP-Squared Injection may offer superior results for your unique biology—enabling truly precision-guided weight loss treatment.

Related Reading

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves